SAN FRANCISCO, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors of the December 8, 2025, deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit filed against aTyr Pharma, Inc. (NASDAQ: ATYR). The litigation follows a catastrophic 83% single-day stock collapse after the company’s flagship drug trial failed to meet its primary endpoint. The lawsuit alleges that aTyr and its executives provided materially false and ...

Key Takeaways IRWD's growth is driven by its U.S. Linzess partnership with ABBV, which posted robust Q3 resultsStronger Linzess demand led IRWD to lift its 2025 revenue outlook following a solid Q3 performance.PBYI's Nerlynx posted $144.2M sales in the first nine months of 2025, up 2.5% year over year.Both Ironwood Pharmaceuticals (IRWD) and Puma Biotechnology (PBYI) are small biotechs, concentrating on the successful commercialization of their respective products with the goal of establishing leadership in ...

Applied Therapeutics Inc. (APLT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Skye Bioscience, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Skye Bioscience securities is from November 4, 2024, to October 3, 2025, inclusive [1]. - Investors who purchased Skye securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [3]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab [4]. - Specifically, it is claimed that nimacimab was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [4]. - The lawsuit asserts that when the true information became public, investors suffered damages as a result [4].

Key Takeaways BEAM and NTLA are compared as gene editing biotechs with pipelines at different development stages.BEAM advances multiple SCD programs and updates its BEAM-101 and BEAM-301 studies across phases.NTLA pushes late-stage in vivo candidates while a clinical hold on nex-z raises safety concerns.Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, NTLA i ...

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best small-cap stocks with huge upside potential according to Redditors. The company is working on oncology therapies designed to target the tumor microenvironment. The company recently announced to acquire Elektrofi, which ca ...

Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the Company has been awarded Foreign Investor of the Year at the 2025 Flanders International Business Awards (FIBA) hosted by Flanders Investment & Trade ( ...

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.Novo Nordisk (NVO +3.51%), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty more pipeline candidates in the works.However, this area is attracting many more challengers looking to capitalize on its fast expansion. One of them is Viking Therapeutics (VKTX +2.34%), a mid-cap biotech. This smaller ...

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000. The net proceeds of the Offering will be used for working capital and general corpora ...